TABLE III.
Clinical outcomes following unconditioned HCT
| Matched Sibling Donor | Unrelated Donor: Adult or Umbilical Cord Blood | |||||||
|---|---|---|---|---|---|---|---|---|
| Overall | NK-Negative | NK-Positive | Overall | NK-Negative | NK-Positive | No Serotherapy | With Serotherapy | |
| Donor T cell Engraftment^ | 63/65 (97%) | 45/46 (98%) | 18/19 (95%) | 34/36 (94%) | 28/28 (100%) | 6/8 (75%) | 22/22 (100%) | 12/14 (86%) |
| 2nd HCT Required^ | 10/65 (15%) | 5/46 (11%) | 5/19 (26%) | 7/36 (19%) | 4/28 (14%) | 3/8 (38%) | 3/23 (13%) | 4/14 (28%) |
| Unconditioned Boost | 6/65 (9%) | 3/46 (7%) | 3/19 (16%) | 3/36 (8%) | 3/28 (11%) | 0/8 (0%) | 2/23 (9%) | 1/14 (7%) |
| Conditioned | 4/65 (6%) | 2/46 (4%) | 2/19 (11%) | 4/36 (11%) | 1/28 (4%) | 3/8 (38%)° | 1/23 (4%) | 3/14 (21%) |
| TRM^ | 2/65 (3%) | 2/46 (4%) | 0/19 (0%) | 6/36 (17%)* | 3/28 (11%) | 3/8 (38%) | 6/22 (27%) | 0/14 (0%) |
| Acute GVHD^ | ||||||||
| Any Grade | 21/63 (33%) | 20/46 (43%) | 1/17 (6%)° | 22/34 (65%)* | 18/28 (64%) | 4/6 (67%) | 16/22 (73%) | 6/12 (50%) |
| Grade II–IV | 14/63 (22%) | 13/46 (28%) | 1/17 (6%) | 17/34 (50%)* | 14/28 (50%) | 3/6 (50%) | 14/22 (64%) | 3/12 (25%) |
| Grade III–IV | 3/63 (5%) | 3/46 (7%) | 0/17 (0%) | 8/34 (24%)* | 6/28 (21%) | 2/6 (33%) | 7/22 (32%) | 1/12 (8%) |
| Chronic GVHD^ | 3/62 (5%) | 2/45 (4%) | 1/17 (6%) | 11/28 (39%)* | 8/24 (33%) | 3/4 (75%) | 8/17 (47%) | 3/11 (27%) |
| Alive at last follow-up | 60/66 (91%) | 43/47 (92%) | 17/19 (89%) | 27/37 (73%)* | 22/29 (76%) | 5/8 (63%) | 13/23 (56%) | 14/14 (100%) |
| Alive without conditioning | 56/66 (85%) | 41/47 (87%) | 15/19 (79%) | 23/37 (62%)* | 21/29 (72%) | 2/8 (25%)° | 12/23 (52%) | 11/14 (79%) |
NK, Natural Killer; TRM, Transplant Related Mortality; GVHD, graft versus host disease
^
Of evaluable patients (see results)
*
P <0.05 compared to sibling donor recipients
°P <0.05 compared to NK-Negative phenotypes